Oppenheimer Asset Management Inc. Raises Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Oppenheimer Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 6.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,191 shares of the specialty pharmaceutical company’s stock after buying an additional 603 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Jazz Pharmaceuticals were worth $1,265,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in JAZZ. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after purchasing an additional 507,234 shares during the period. Darwin Global Management Ltd. bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at approximately $59,668,000. Dimensional Fund Advisors LP lifted its holdings in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after buying an additional 320,724 shares during the period. Ameriprise Financial Inc. lifted its holdings in Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after buying an additional 315,608 shares during the period. Finally, GMT Capital Corp increased its stake in shares of Jazz Pharmaceuticals by 140.0% during the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after buying an additional 296,800 shares during the period. Institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. HC Wainwright raised their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Finally, Truist Financial lifted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $184.00.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $106.90 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a 50-day moving average price of $108.63 and a 200-day moving average price of $119.57. The firm has a market cap of $6.47 billion, a PE ratio of 14.25, a P/E/G ratio of 4.64 and a beta of 0.33. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analysts’ expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm’s quarterly revenue was down .5% on a year-over-year basis. During the same period last year, the firm posted $2.68 earnings per share. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 500 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $107.90, for a total transaction of $53,950.00. Following the completion of the transaction, the chief executive officer now directly owns 438,473 shares of the company’s stock, valued at $47,311,236.70. The trade was a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Seamus Mulligan bought 1,621 shares of the business’s stock in a transaction on Monday, May 12th. The stock was bought at an average cost of $103.00 per share, with a total value of $166,963.00. Following the transaction, the director now owns 101,621 shares in the company, valued at $10,466,963. This trade represents a 1.62% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 3,000 shares of company stock valued at $355,925. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.